Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL

Molecular Cancer Therapeutics
Michela BardiniGianni Cazzaniga

Abstract

MLL-rearranged acute lymphoblastic leukemia (ALL) occurring in infants is a rare but very aggressive leukemia, typically associated with a dismal prognosis. Despite the development of specific therapeutic protocols, infant patients with MLL-rearranged ALL still suffer from a low cure rate. At present, novel therapeutic approaches are urgently needed. Recently, the use of small molecule inhibitors targeting the epigenetic regulators of the MLL complex emerged as a promising strategy for the development of a targeted therapy. Herein, we have investigated the effects of bromodomain and extra-terminal (BET) function abrogation in a preclinical mouse model of MLL-AF4+ infant ALL using the BET inhibitor I-BET151. We reported that I-BET151 is able to arrest the growth of MLL-AF4+ leukemic cells in vitro, by blocking cell division and rapidly inducing apoptosis. Treatment with I-BET151 in vivo impairs the leukemic engraftment of patient-derived primary samples and lower the disease burden in mice. I-BET151 affects the transcriptional profile of MLL-rearranged ALL through the deregulation of BRD4, HOXA7/HOXA9, and RUNX1 gene networks. Moreover, I-BET151 treatment sensitizes glucocorticoid-resistant MLL-rearranged cells to prednisolone i...Continue Reading

References

Apr 20, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Daniel H LiJane R Parnes
Oct 25, 2007·Nature Reviews. Cancer·Andrei V Krivtsov, Scott A Armstrong
Nov 4, 2008·Cancer Cell·Andrei V KrivtsovScott A Armstrong
Dec 6, 2008·Blood·Joerg FaberScott A Armstrong
Dec 11, 2008·Journal of Clinical Immunology·Hsin-Jung Wu, Subbarao Bondada
Jan 15, 2009·Genes & Development·Matthew G GuentherRichard A Young
Jul 20, 2010·Nature·Takahiro ItoTannishtha Reya
Aug 5, 2011·Nature·Johannes ZuberChristopher R Vakoc
Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Oct 12, 2012·International Journal of Hematology·Yue ZhangGang Huang
Jun 27, 2013·Blood·Scott R DaigleRoy M Pollock
Aug 28, 2013·The Journal of Clinical Investigation·Susumu GoyamaJames C Mulloy
Apr 17, 2014·Cell Cycle·Marieke H van der LindenRonald W Stam
Apr 26, 2014·Blood·Theresa PlackeStefan Fröhling
Jul 1, 2014·Proceedings of the National Academy of Sciences of the United States of America·Joydeep BhaduryJonas A Nilsson
Nov 18, 2014·Pediatric Blood & Cancer·ZoAnn E DreyerBruce M Camitta
Feb 11, 2015·The Journal of Clinical Investigation·Sun-Mi ParkMichael G Kharas
Sep 15, 2015·Nature·Chun Yew FongMark A Dawson
Jan 7, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeyran ShahbaziTao Liu
Jun 14, 2016·Nature Structural & Molecular Biology·Omer GilanMark A Dawson
Oct 13, 2016·OncoTargets and Therapy·Sameem M AbedinHidayatullah G Munshi
Jan 20, 2017·ELife·Linchong Sun, Ping Gao
Jan 20, 2017·ELife·Fraser AirdUNKNOWN Reproducibility Project: Cancer Biology
Jun 28, 2017·ELife·Xiaochuan ShanUNKNOWN Reproducibility Project: Cancer Biology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.